AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
The Cerevel deal aligns seamlessly with its established strategy, introducing a portfolio of five clinical-stage and two preclinical candidates targeting various ailments like schizophrenia, Parkinson's disease (PD), and mood disorders. This strategic move is anticipated to fuel growth from the latter part of this decade well into the 2030s.Wednesday, AbbVie Inc (NYSE:ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ:CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the transaction anticipated to close in the middle of 2024.
週三，艾伯維公司（紐約證券交易所代碼：ABBV）同意收購Cerevel Therapeutics Holdings Inc（納斯達克股票代碼：CERE），總股本價值約爲87億美元，合每股現金45美元，交易預計將於2024年中期完成。
The deal comes just a couple of days after AbbVie agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) for $31.26 per share in cash, equivalent to a total equity value of approximately $10.1 billion.
該交易是在艾伯維同意以每股31.26美元的現金收購ImmunoGen Inc（納斯達克股票代碼：IMGN）幾天後達成的，相當於總股本價值約爲101億美元。
William Blair highlights AbbVie's clear interest in expanding its foothold in neuroscience, as evidenced by their expressed intent.
威廉·布萊爾強調艾伯維顯然有興趣擴大其在神經科學領域的立足點，他們表達的意圖就證明了這一點。
The Cerevel deal aligns seamlessly with its established strategy, introducing a portfolio of five clinical-stage and two preclinical candidates targeting various ailments like schizophrenia, Parkinson's disease (PD), and mood disorders. This strategic move is anticipated to fuel growth from the latter part of this decade well into the 2030s.
Cerevel的交易與其既定戰略無縫一致，推出了針對精神分裂症、帕金森氏病（PD）和情緒障礙等各種疾病的五種臨床階段和兩種臨床前候選藥物組成的產品組合。預計這一戰略舉措將推動從本十年的後半期一直持續到2030年代的增長。
However, the potential scrutiny from the Federal Trade Commission (FTC) remains a significant concern for analysts.
但是，聯邦貿易委員會（FTC）的潛在審查仍然是分析師嚴重關注的問題。
Given that Vraylar, estimated to generate $2.7 billion in revenue in 2023, is approved for schizophrenia, bipolar I disorder, and adjunctive major depressive disorder, it wouldn't be surprising if the deal undergoes FTC examination.
鑑於Vraylar預計將在2023年創造27億美元的收入，獲准用於精神分裂症、I型躁鬱症和輔助性重度抑鬱症，如果該交易經過聯邦貿易委員會的審查也就不足爲奇了。
AbbVie already boasts an approved PD product (Duopa/Duodopa) yielding approximately $450 million in annual revenue and anticipates approval for ABBV-951 (subcutaneous levodopa/carbidopa) in the first half of 2024, further strengthening its position in this therapeutic area.
AbbVie已經擁有一款獲得批准的PD產品（Duopa/Duodopa），年收入約爲4.5億美元，並預計 ABBV-951（皮下左旋多巴/卡比多巴）將在2024年上半年獲得批准，進一步鞏固其在這一治療領域的地位。
Price Action: ABBV shares are up 1.06% at $147.94 on the last check Thursday.
價格走勢：週四上一次支票，ABBV股價上漲1.06％，至147.94美元。
譯文內容由第三人軟體翻譯。
